Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Metastatic Triple-Negative Breast Cancer
NCT01738438Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 2013
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in triple negative breast cancer (TNBC), sponsored by Dana-Farber Cancer Institute. Started Feb 2013; status: completed.
02
Drugs
cabozantinib
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01738438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01738438.